Learn More
D17DT consists of the GnRH decapeptide linked to diphtheria toxoid. The aim of this pilot study was to assess the tolerance of D17DT and the production of anti-GnRH antibodies from two doses, 30 and 100 microg, in patients with locally advanced prostate cancer. Twelve patients with histologically proven prostate cancer in whom hormonal therapy was indicated(More)
PURPOSE G17DT is a gastrin immunogen, raising antibodies that blockade gastrin-stimulated growth. The aim of the study was to characterise antibody response and assess safety and tolerability of G17DT given to patients with gastric cancer. EXPERIMENTAL DESIGN G17DT was administered to 52 patients with gastric adenocarcinoma at weeks 0, 2 and 6 by(More)
2511 Background: Pancreatic adenocarcinomas express CCK-2 receptors and respond to amidated gastrins resulting in transcriptional activation of EGF receptor ligands, matrix metalloproteinases and anti-apoptotic factors which collectively increase tumorigenic potential. The gastrin gene may also be activated resulting in gly-gastrin secretion. G17DT, a(More)
OBJECTIVES This study aimed to investigate G17DT, an immunogen producing neutralizing antibodies against the tumor growth factors amidated and glycine-extended forms of gastrin-17, in the treatment of pancreatic cancer. METHODS A randomized, double-blind, placebo-controlled, group-sequential multicenter trial of G17DT in patients with advanced pancreatic(More)
AIM The aim of this study was to determine the ability of G17DT to generate anti-gastrin antibodies in jaundiced patients with biliary obstruction due to advanced pancreatic cancer. METHODS G17DT was administered to 41 patients with advanced pancreatic adenocarcinoma by intramuscular (i.m.) injection at a dose of 250mcg at weeks 0, 1 and 3 of the study.(More)
OBJECTIVES We have previously reported the ability of D17DT (formerly GnRH-DT) vaccination to produce castrate levels of androgens in men with advanced prostate cancer. This study examines the efficacy and tolerability of 3 and 15 micrograms of D17DT in 12 patients with advanced prostate cancer to establish a dose-response relationship. METHODS 12(More)
4108 Background: In a Phase III pancreatic cancer trial combining G17DT with gemcitabine (Gem) vs Gem alone [ASCO 2005, Abstract 4012], a significant survival effect, independent of baseline KPS, was seen in patients with gastrin antibody response (Placebo + Gem 178 days vs 264 for antibody responders > 16U, p = 0.03). A consistent criticism of such(More)